The HDL (high-density lipoprotein)-associated enzyme PON (paraoxonase)-1 protects LDL (lowdensity lipoprotein) from oxidative modification in vitro, although it is unknown if this antiatherogenic action occurs in vivo. In a cross-sectional study of 58 Type II diabetic subjects and 50 controls, we examined the fasting plasma LDL basal conjugated diene concentration [a direct measurement of circulating oxLDL (oxidatively modified LDL)], lipoprotein particle size by NMR spectroscopy, PON-1 polymorphisms (coding region polymorphisms Q192R and L55M, and gene promoter polymorphisms − 108C/T and − 162G/A), PON activity (with paraoxon or phenyl acetate as the substrates) and dietary antioxidant intake. Plasma oxLDL concentrations were higher in Type II diabetic patients (males, P = 0.048; females, P = 0.009) and unrelated to NMR lipoprotein size, PON-1 polymorphisms or PON activity (with paraoxon as the substrate) in any group. In men with Type II diabetes, however, there was a direct relationship between oxLDL concentrations and PON activity (with phenyl acetate as the substrate; r = 0.611, P = 0.0001) and an atherogenic NMR lipid profile in those who were PON-1 55LL homozygotes. Circulating oxLDL concentrations in vivo were unrelated to PON-1 genotypes or activity, except in male Type II diabetics where there was a direct association between PON activity (with phenyl acetate as the substrate) and oxLDL levels. These in vivo data contrast with in vitro data, and may be due to confounding by dietary fat intake. Male Type II diabetic subjects with PON-1 55LL homozygosity have an atherogenic NMR lipid profile independent of LDL oxidation. These data do not support an in vivo action of PON on LDL oxidation.
INTRODUCTION
oxLDLs [oxidatively modified LDLs (low-density lipoproteins)] in the plasma and arterial wall are important in the development of atherosclerosis [1, 2] . The increased risk of atherosclerosis in Type II diabetes [3] might be due, in part, to increased oxidative susceptibility of LDL with unusual physicochemical properties [4] , to variations in and these polymorphisms are associated with a 40-fold interindividual variability in enzyme activity [8] . In addition, functional PON-1 gene promoter polymorphisms at − 108C/T and − 162G/A are described [8] , and PON appears to protect isolated LDL from oxidative damage in vitro [9, 10] . PON activity is also influenced by diet, insulin sensitivity, inflammation, HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors (statins), smoking and alcohol intake, which have been reviewed recently in detail [8] . In particular, most studies have described significantly lower plasma PON activity in Type II diabetes [8] , although this is not a consistent observation [11] [12] [13] [14] . The lower plasma PON activity in Type II diabetes in some studies may be due to increased enzyme glycation, impaired antioxidant defences or differences in diet [8] , but these data and in vitro evidence have led to the suggestion that variability in PON activity, particularly in Type II diabetes, might increase the risk of atherosclerosis, mediated through impaired protection of LDL from oxidative modification. However, recent large prospective studies and meta analyses have failed to find any consistent significant association between PON-1 polymorphisms and cardiovascular outcomes [15] [16] [17] , no prospective study has shown any relationship between PON activity and cardiovascular outcomes, and there are no data to suggest that plasma oxLDL levels in vivo are correlated with variability in PON activity.
Surrogate measurements for plasma oxLDL, such as the susceptibility of plasma LDL to copper-induced formation of conjugated dienes in vitro, are widely used [3] , but it is not clear how these methods relate to in vivo changes [18] [19] [20] [21] [22] [23] . In vivo methods for measuring oxLDL include the direct measurement of these baseline diene conjugates in plasma LDL [24] , and oxLDL measured in this way is related to surrogates for atherosclerotic load [25] and expression of the LDL scavenger receptor CD36 [26] . In view of the discordance between the in vitro LDL-protective effect of PON and the negative meta analyses, and the absence of any data on PON activity and oxLDL data in vivo, we examined plasma oxLDL concentrations in relation to PON activity and PON-1 genotype in subjects without and with Type II diabetes.
METHODS

Patients and sample size
This study was carried out in accordance with the Declaration of Helsinki (2000) and after local Ethical Committee approval and written informed consent. We studied 58 Caucasian subjects with Type II diabetes (38 male and 20 female) and 50 Caucasian controls without Type II diabetes (18 male and 32 female). Subjects were recruited if they were aged between 40 and 70 years old, and were excluded if they were active smokers, had a clinical history of confirmed myocardial infarction or angina, if they were taking aspirin, any lipid-lowering medication, antioxidant supplement, n − 3 fatty acid supplement, or if they had microalbuminuria or macroproteinuria.
The diabetes subjects were all diagnosed after the age of 40 years and had no history of ketosis, but patients taking insulin were not excluded if they had been managed with oral hypoglycaemics for at least 1 year prior to conversion to insulin. Patients taking gliclazide, which has antioxidant properties, were excluded [27] . Of the 38 males with diabetes, 30 were receiving insulin, four were taking a sulphonylurea/metformin combination and four were taking metformin alone. Of the 20 females with diabetes, 15 were receiving insulin, two were taking sulphonylurea alone, two metformin alone and one was diet controlled. Female patients were post-menopausal, and post-menopausal hormone-replacement therapy was an exclusion criterion.
All controls had a fasting plasma glucose < 6.1 mmol/l, and all Type II patients managed with diet alone had a fasting blood glucose > 7.0 mmol/l [28] . In the absence of adequate data on LDL baseline diene conjugate concentrations in Type II diabetes, initial sample sizes were selected to provide more than 90 % power at the 5 % level to detect one S.D. difference in oxLDL concentrations using the methods described below between groups and subgroups based on the findings of Toikka et al. [29] . This difference seems biologically plausible, as men with hypertension and surrogate evidence of vascular disease have a mean LDL basal conjugated diene concentration more than 2 S.D. above the control mean [29] .
After an overnight 15 h fast, subjects omitted all morning medication and underwent peripheral venesection for a single 80 ml sample of venous blood. All subjects then undertook an unweighed 3 day food diary.
Plasma LDL baseline conjugated dienes (oxLDL)
Plasma LDL baseline conjugated diene concentrations (oxLDL) were measured using the method described by Ahotupa and Vasankari [24] . In summary, serum LDLs were precipitated by buffered heparin (0.064 M trisodium citrate adjusted to pH 5.05 with 5 M HCl, and containing 50 000 international units/l heparin). Insoluble lipoproteins were sedimented by centrifugation at 1000 g for 10 min, and the pellet was resuspended in 1 ml of 0.1 M sodium phosphate buffer (pH 8.0, containing 0.9 % NaCl). Lipids were extracted from 100 µl of LDL by chloroform/methanol, dried under nitrogen, then redissolved in cyclohexane and analysed spectrophotometrically at 234 nm [24] . Absorbance units (A 234 − A 300 ) were converted into molar units using the molar absorption coefficient 2.95 × 10 4 M −1 · cm −1 . Samples were analysed in real-time and not batched. We have shown previously [26] that oxLDL measured using this technique is directly related to monocyte CD36 LDL scavenger receptor expression. Others have shown that LDL baseline conjugated dienes are directly related to levels of carotid atherosclerosis [25] and oxLDL measured antibody titres against oxLDL, and are the same oxidation product as that generated in vitro by copper oxidation [18] .
PON-1 polymorphisms and plasma PON activity
Polymorphisms in the PON-1 coding region at positions 192 and 55 and in the PON-1 gene promoter were analysed using standard PCR and restriction digest methods as described previously [30, 31] . PON-1 activity in enzymatic assay was based on the method described by Gan et al. [32] . Paraoxon (O,O-diethyl p-nitrophenyl phosphate; 1.0 mM) was used as a substrate, and enzyme activity was measured at 37
• C in 50 mM Tris/HCl buffer (pH 6.8) containing 1.0 mM CaCl 2 , using an automated biochemistry analyser (COBAS mira plus; Roche). Serum was added to start the reaction, and the increase in A 405 was recorded. The amount of p-nitrophenol formed/ min was calculated from the molar absorption coefficient at pH 6.8 (7480 M −1 · cm −1 ). PON activity was expressed as nmol p-nitrophenol formed/min, and also corrected for concentrations of the HDL-associated Apo-A1 (apolipoprotein A1). PON-1 arylesterase activity was determined as the rate of phenyl acetate hydrolysis catalysed by serum in a cuvette with 4.4 mM phenyl acetate in 50 mM Tris/acetate (pH 7.8) containing 20 mM CaCl 2 at 37
• C. The hydrolysis of phenyl acetate was monitored at 270 nm with a molar absorption coefficient at 270 nm of 1310 litre · mol −1 · cm −1 . Arylesterase activity (with phenyl acetate as a substrate) reflects approximately the same level of activity per unit of enzyme with PON-1 for both the Q or R genotypes and is the best indicator of the concentration of enzyme protein. Data for nanomolar PON activity were estimated as:
where Abs/min is blank-corrected change in absorbance/min, ε is the molar absorbance coefficient (7480 litre · mol −1 · cm −1 ), tv is the total reaction volume (0.3 ml), sv is the sample reaction volume (0.04 ml), and d is the light path (0.6 cm). The conversion of molar into nanomolar absorbance coefficient (in litre · mol −1 · cm −1 ) was achieved by multiplying by 10 9 .
Plasma lipoprotein analysis by NMR spectroscopy
Plasma lipoprotein subclass analyses were undertaken using NMR spectroscopy (NMR LipoProfile ® ; LipoMed) as reported previously [33] .
Plasma lipid and lipoprotein measurements
Plasma lipid profiles were measured using commercially available kits (Roche) with calculation of LDLcholesterol [34] . Apo-A1 and Apo-B (apolipoprotein B) concentrations in EDTA-treated plasma were determined by turbidimetry and nephelometry using commercially available kits (ABX).
Plasma antioxidant concentrations
Plasma α-tocopherol and carotenoid concentrations were measured using a modified HPLC method [35] and corrected for plasma total cholesterol concentrations.
Dietary intake and analysis
Dietary analyses were undertaken using commercially available diet analysis software (Compeat Nutritional analysis, CompEat 5.0; Nutrition Systems) based on 3 day unweighed food diaries.
Statistical analysis
Normally distributed variables are shown as means (S.D.), and non-normally distributed variables as medians (interquartile range). Differences between groups were analysed with an unpaired Student t test or with a MannWhitney U test, as appropriate. Relationships between variables within a group were analysed by simple linear regression. Stepped multiple regression with entry of a variable into the regression equation if P was < 0.1 on simple linear regression was used to examine relationships between dependent and independent variables within groups. Binary variables, such as PON-1 polymorphisms, were entered into these equations as a continuous dummy variable. Data analyses were undertaken on commercially available statistical software (Statview 4.0 for Windows; Adept Scientific).
RESULTS
Clinical features
The diabetic groups were in moderate glycaemic control based on HbA1c (glycosylated haemoglobin) data. Females with Type II diabetes were more centrally obese, with a significantly higher systolic blood pressure (P < 0.01) and plasma triacylglycerols (triglycerides; P < 0.05), and lower plasma HDL concentrations (P < 0.001), than female controls. These variables did not differ significantly between males with Type II diabetes and male controls (Table 1) .
Plasma LDL baseline diene conjugates (oxLDL)
Mean plasma oxLDL concentrations were significantly higher in both male (P = 0.043) and female (0.009) Type II diabetic groups than in controls ( Table 2) . (13) 81 (14) 80 (11) 82 (10) 
Plasma lipoprotein analyses by NMR spectroscopy
In males, NMR particle size profiles did not differ significantly between Type II diabetic patients and controls (Table 2 ). In particular, mean LDL particle size and LDL particle size distribution were very similar. In females, NMR particle profiles showed that the Type II diabetic group had a lower mean LDL particle size (P = 0.004), a different LDL particle size distribution with less large LDL (P = 0.007), and a lower proportion of HDL in large HDL particles (P = 0.05) than in female controls (Table 2) .
Serum PON activity
Serum PON activity (PON or arylesterase) corrected or uncorrected for plasma Apo-A1 concentrations did not differ significantly between the male or female Type II diabetic groups and matched controls (Tables 2  and 3 ). Corrected activities by subgroup and genotype are shown in 
Determinants of plasma oxLDL concentrations
Male Type II diabetic patients
Only total fat intake (r = 0.36, P = 0.035), saturated fat intake (r = 0.34, P = 0.048) and PON activity with phenyl acetate as the substrate (r = 0.543, P = 0.0006 for activity corrected for Apo-A1; r = 0.61, P = 0.0001 for uncorrected activity) were correlated with oxLDL concentrations. The latter relationship was a positive direct relationship. On stepped multiple regression, only arylesterase activity (with phenyl acetate as the substrate) was independently and directly related to oxLDL concentrations. LDL particle size (P = 0.88) was not significantly related.
Male controls
Only LDL mean particle size was independently related to oxLDL concentrations (r = 0.51, P = 0.042), and there was no significant relationship between oxLDL and corrected PON activity using either substrate (r = 0.77).
Female Type II diabetic patients
No independent relationship between oxLDL and any variable was detected; in particular there was no relationship with LDL particle size (P = 0.48) or corrected PON activity using either substrate (both P > 0.55). 
Female controls
No independent relationship between oxLDL and any variable was detected; in particular there was no relationship with LDL particle size (P = 0.51) or corrected PON activity using either substrate (both P > 0.3).
PON-1 genotype, PON activity and oxLDL
In subgroups genetically homogeneous for enzymespecific activity (192QQ and 55MM), there was a significant direct relationship between corrected PON activity (with phenyl acetate as the substrate) and oxLDL in the male Type II diabetic patients who were 192QQ homozygous (r = 0.72, P = 0.002; n = 16). There were no other significant relationships within other subgroups (all P > 0.2).
PON-1 genotype and NMR lipoprotein analysis
Male Type II diabetic patients homozygous for the LL allele at position 55 of PON-1 differed significantly in lipid profile and NMR lipoprotein analysis compared with male Type II diabetic patients with one or more LL allele at this position (Table 4) . These groups did not differ significantly in any other variable (results not shown; all P > 0.25). These differences were not apparent in male controls or in females without or with Type II diabetes (results not shown; all P > 0.3). Similar changes were not apparent for the polymorphism at position 192 or promoter polymorphisms.
Dietary intake and plasma antioxidant profiles
Male and female patients with Type II diabetes did not differ significantly from controls in any measured dietary component or any plasma antioxidant concentration, except for plasma β-carotene, which was significantly lower (P = 0.006) in female Type II diabetic patients (results not shown). There was no relationship between plasma α-tocopherol levels and PON-1 activity in any group (results not shown).
DISCUSSION
Direct detection of fatty acid oxidation products (conjugated dienes) in plasma LDL is a useful and nonsurrogate measurement of LDL oxidative modification in vivo [24] . NMR and HPLC analyses indicate that the lipid oxidation products detected are predominantly linoleic acid oxidation derivatives [24] , and are the same oxidation product detected in vitro by the common surrogate method of copper-stimulated oxidation [18] used in previous in vitro studies of PON [8] . LDLconjugated diene concentrations are directly related to the prevalence and degree of atherosclerotic disease [24, 25] , and to the levels of expression of the monocyte/ macrophage LDL scavenger receptor CD36 [26] . The levels of these oxidation products were significantly higher in both male and female Type II diabetic patients compared with controls. We found that PON activity was lower, but not significantly so, in the diabetic compared with the control groups, which is much less common than the observation of a significantly lower PON activity in Type II diabetes [8] , but which has nevertheless been described [11] [12] [13] [14] . The pre-specified exclusions in the present study population would have reduced the confounding effects of gender, ethnicity, preexisting cardiovascular disease, medication, hormonereplacement therapy, smoking and diabetic nephropathy on PON activity that may be apparent in other studies [8, [36] [37] [38] [39] . PON-1 gene polymorphisms lead to variability in PON enzyme activity, and some cross-sectional and case-control studies have described an association between cardiovascular disease or cardiovascular events and PON-1 gene polymorphisms in Type II diabetes and controls [11, 40] ; these studies have been reviewed recently [8, 16] . PON in vitro appears to 'protect' LDL from the copper-induced generation of oxidation products, particularly LDL-conjugated dienes [10] and, because of this, it has been proposed that any associations between PON-1 gene polymorphisms and cardiovascular disease could be mediated through a similar LDL-protective effect in vivo [10] . However, in the present study, we found no relationship between PON activity and oxLDL concentrations, and subgroups with very different PON enzyme activities did not differ in oxLDL concentrations. Surprisingly, in the male Type II diabetic patients, there was a strong, independent and direct relationship between PON activity (with phenyl acetate as the substrate) and in vivo levels of oxLDL, a counterintuitive finding in light of the in vitro data on the protective actions of PON on LDL oxidation [10] . The unusual direction of this relationship may be due to unmeasured confounding variables; for instance, oxLDL can induce expression of interleukin-6 from some cell types [41] , which has, in turn, been shown to increase PON-1 gene expression in HepG2 cells [42] . Another possible confounder is that of dietary fat intake which was weakly related to both oxLDL levels and to PON activity in the male Type II diabetic patients, as has been described previously [43] , and which could account for the restriction of this finding to male Type II diabetic patients. Our data suggest that PON activity in vivo does not appear to be related to lower plasma oxLDL levels, and these are in agreement with recent data from heterogeneous populations with Type II diabetes using an oxidized LDL antibody as a surrogate for oxLDL in a population [21] or oxLDL measured using an ELISA method [44] . In the latter study, a large proportion of Type II diabetic patients had established cardiovascular disease and many (30 %) were receiving a statin, which could perhaps have blunted any relationship between oxLDL and PON activity [45] .
We also found that males with Type II diabetes who were PON-1 55LL homozygous had a very different lipid and lipoprotein profile compared with male Type II diabetic patients with an M allele. The pattern of higher serum triaclyglycerols and VLDL (very-LDL) particle size, lower HDL and Apo-A1 concentrations and smaller LDL particles with less large LDL is typical of the atherogenic pattern described as part of the 'insulin resistance' syndrome [46] . A similar observation has been made before, but only in subjects without diabetes. Barbieri et al. [47] found that controls without diabetes who were PON-1 55LL homozygous were more centrally obese, insulin resistant, hypertensive and had a lower HDL-cholesterol level than those with an M allele at position 55. Also, young male subjects without diabetes who are PON-1 55LL homozygous appear to have less effective glucose disposal than subjects with an M allele, particularly when there is a parental history of coronary artery disease [48] . The present findings in the Type II diabetic population suggest one possible link between PON-1 55LL, atherogenic lipoprotein profiles and cardiovascular disease and would be compatible with clinical studies which have shown that PON-1 55LL homozygosity is associated with carotid atherosclerosis [40] . This association between LL homozygosity and an atherogenic lipoprotein profile could reflect less effective antioxidant defences and increased levels of oxidative stress in LL homozygotes, in turn leading to impaired B-cell function or insulin sensitivity mediated through increased lipid oxidation products [49] . There is some evidence to support an increased level of oxidative DNA damage and lipid oxidation products in PON-1 55LL carriers with Type II diabetes [50] , although we have shown that PON-1 192 polymorphisms are not associated with oxidative DNA damage or LDL oxidative susceptibility [51] . It is not clear why this association should only be apparent in males with Type II diabetes, but if PON-1 55LL homozygotes have less effective antioxidant defences, it is possible that this would be expressed most in males who are characterized by increased oxidative stress and damage compared with females [52] .
One significant determinant of LDL-conjugated diene formation in the male Type II diabetic patients was total fat intake, which was not evident in controls. Lipid oxidation products in the diet can be incorporated directly into plasma lipoproteins without generation in vivo [5] , a process exaggerated in animal models of diabetes [53] , perhaps because of changes in the gut wall oxidation balance [54] . If changes in oxidation balance were a mechanism for this association, again it is possible that this would be apparent in males with diabetes [52] . One weakness of the present study is that unaccounted for variability in oxLDL may be a function of differing LDL fatty acid content [55] , and lipoprotein fatty acid analyses were not undertaken in the present study. In addition, the present data only apply to the plasma compartment and cannot be extended to the vessel wall or to potential oxLDL generation within the vessel wall, and our data interpretation only applies to the enzymeassociated LDL-protective effects of PON-1 [56] .
In summary, we have demonstrated elevated plasma oxLDL levels in Type II diabetes and that variability in PON activity associated with PON-1 genotypes is not associated with significant variability in oxLDL levels. In men with Type II diabetes, there is an unexpected independent direct relationship between oxLDL and PON activity (with phenyl acetate as the substrate), possibly due to confounding by dietary fat intake, and a novel independent association between the PON-1 55LL polymorphism and an atherogenic lipoprotein phenotype in male Type II diabetic patients. These data do not support an in vivo LDL protective action for PON in contrast with earlier in vitro data.
